Format
Sort by
Items per page

Send to

Choose Destination

Best matches for mitragynine therapeutic potential:

The therapeutic potential of kratom. Grundmann O et al. Addiction. (2018)

Pharmacologic and clinical assessment of kratom. White CM et al. Am J Health Syst Pharm. (2018)

Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Hemby SE et al. Addict Biol. (2019)

Search results

Items: 1 to 20 of 24

1.

Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.

Harun N, Johari IS, Mansor SM, Shoaib M.

Psychopharmacology (Berl). 2019 Dec 12. doi: 10.1007/s00213-019-05418-6. [Epub ahead of print]

PMID:
31832720
2.

Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: present knowledge and future directions in perspective of pain.

Ramachandram DS, Damodaran T, Zainal H, Murugaiyah V, Ramanathan S.

J Basic Clin Physiol Pharmacol. 2019 Oct 30;31(1). pii: /j/jbcpp.2020.31.issue-1/jbcpp-2019-0138/jbcpp-2019-0138.xml. doi: 10.1515/jbcpp-2019-0138. Review.

PMID:
31665120
3.

7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects.

Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, Ansonoff M, Gassaway MM, Pintar JE, Pasternak GW, Javitch JA, Majumdar S, Sames D.

ACS Cent Sci. 2019 Jun 26;5(6):992-1001. doi: 10.1021/acscentsci.9b00141. Epub 2019 May 29.

4.

Kratom policy: The challenge of balancing therapeutic potential with public safety.

Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D.

Int J Drug Policy. 2019 Aug;70:70-77. doi: 10.1016/j.drugpo.2019.05.003. Epub 2019 May 16.

5.

Mitragyna speciosa: Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples.

Meireles V, Rosado T, Barroso M, Soares S, Gonçalves J, Luís Â, Caramelo D, Simão AY, Fernández N, Duarte AP, Gallardo E.

Medicines (Basel). 2019 Mar 4;6(1). pii: E35. doi: 10.3390/medicines6010035. Review.

6.

Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction.

Hughes RL.

Forensic Sci Med Pathol. 2019 Mar;15(1):110-113. doi: 10.1007/s12024-018-0049-9. Epub 2018 Nov 29.

PMID:
30498933
7.

Lateral Flow Assessment and Unanticipated Toxicity of Kratom.

Smith LC, Lin L, Hwang CS, Zhou B, Kubitz DM, Wang H, Janda KD.

Chem Res Toxicol. 2019 Jan 22;32(1):113-121. doi: 10.1021/acs.chemrestox.8b00218. Epub 2018 Nov 16.

8.

Abuse liability of mitragynine assessed with a self-administration procedure in rats.

Yue K, Kopajtic TA, Katz JL.

Psychopharmacology (Berl). 2018 Oct;235(10):2823-2829. doi: 10.1007/s00213-018-4974-9. Epub 2018 Jul 23.

PMID:
30039246
9.

Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.

Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR.

Addict Biol. 2019 Sep;24(5):874-885. doi: 10.1111/adb.12639. Epub 2018 Jun 27.

PMID:
29949228
10.

The therapeutic potential of kratom.

Grundmann O, Brown PN, Henningfield J, Swogger M, Walsh Z.

Addiction. 2018 Oct;113(10):1951-1953. doi: 10.1111/add.14371. Epub 2018 Jul 13. No abstract available.

PMID:
29949213
11.

Kratom: a dangerous player in the opioid crisis.

Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO.

J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):107-110. doi: 10.1080/20009666.2018.1468693. eCollection 2018.

12.

The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Henningfield JE, Fant RV, Wang DW.

Psychopharmacology (Berl). 2018 Feb;235(2):573-589. doi: 10.1007/s00213-017-4813-4. Epub 2017 Dec 23. Review.

13.

Pharmacologic and clinical assessment of kratom.

White CM.

Am J Health Syst Pharm. 2018 Mar 1;75(5):261-267. doi: 10.2146/ajhp161035. Epub 2017 Dec 18. Review.

PMID:
29255059
14.

Kratom use and mental health: A systematic review.

Swogger MT, Walsh Z.

Drug Alcohol Depend. 2018 Feb 1;183:134-140. doi: 10.1016/j.drugalcdep.2017.10.012. Epub 2017 Dec 7. Review.

PMID:
29248691
15.

The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse.

Kruegel AC, Grundmann O.

Neuropharmacology. 2018 May 15;134(Pt A):108-120. doi: 10.1016/j.neuropharm.2017.08.026. Epub 2017 Aug 19. Review.

PMID:
28830758
16.

Effects of alkaloid-rich extract from Mitragyna speciosa (Korth.) Havil. on naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice.

Cheaha D, Reakkamnuan C, Nukitram J, Chittrakarn S, Phukpattaranont P, Keawpradub N, Kumarnsit E.

J Ethnopharmacol. 2017 Aug 17;208:129-137. doi: 10.1016/j.jep.2017.07.008. Epub 2017 Jul 5.

PMID:
28687506
17.

A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom.

Brown PN, Lund JA, Murch SJ.

J Ethnopharmacol. 2017 Apr 18;202:302-325. doi: 10.1016/j.jep.2017.03.020. Epub 2017 Mar 19. Review.

PMID:
28330725
18.

Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential.

Chang-Chien GC, Odonkor CA, Amorapanth P.

Pain Physician. 2017 Jan-Feb;20(1):E195-E198.

19.

Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature.

Singh D, Narayanan S, Vicknasingam B.

Brain Res Bull. 2016 Sep;126(Pt 1):41-46. doi: 10.1016/j.brainresbull.2016.05.004. Epub 2016 May 10. Review.

PMID:
27178014
20.

Neurobiology of Kratom and its main alkaloid mitragynine.

Suhaimi FW, Yusoff NH, Hassan R, Mansor SM, Navaratnam V, Müller CP, Hassan Z.

Brain Res Bull. 2016 Sep;126(Pt 1):29-40. doi: 10.1016/j.brainresbull.2016.03.015. Epub 2016 Mar 25. Review.

PMID:
27018165

Supplemental Content

Loading ...
Support Center